Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 11 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 16

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Afamelanotide
   CLINUVEL EUROPE LIMITED
      2022   Phase 2   EUCTR2021-001419-10-ES   Belgium;Spain
      2022   Phase 2   EUCTR2021-001419-10-BE   Belgium;Spain
      2021   Phase 2   EUCTR2019-000597-34-DE   Germany
   CLINUVEL EUROPE LTD
      2021   Phase 2   EUCTR2021-003642-20-DE   Germany
   Clinuvel Europe Limited
      2022   Phase 2   NCT05370235   Belgium;Spain
      2021   Phase 2   NCT05159752   Germany
Biospecimen collection
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States
Ipilimumab
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States
Isotretinoin
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1991   -   NCT00025012   United States
Liposomal T4n5 lotion
   Applied Genetics
      1996   Phase 3   NCT00002811   Germany;United Kingdom;United States
Nivolumab
   National Cancer Institute (NCI)
      2021   Phase 1   NCT04500548   Canada;United States
Scenesse
   CLINUVEL EUROPE LIMITED
      2022   Phase 2   EUCTR2021-001419-10-ES   Belgium;Spain
      2022   Phase 2   EUCTR2021-001419-10-BE   Belgium;Spain
      2021   Phase 2   EUCTR2019-000597-34-DE   Germany
   CLINUVEL EUROPE LTD
      2021   Phase 2   EUCTR2021-003642-20-DE   Germany
Trabectedina
   PharmaMar S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-ES   Belgium;Spain
Trabectedine
   Pharma Mar, S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-BE   Belgium;Spain
Yondelis 0,25 MG polvo para concentrado para solucióN para perfusióN
   PharmaMar S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-ES   Belgium;Spain
Yondelis 1 MG polvo para concentrado para solucióN para perfusióN
   PharmaMar S.A. Sociedad Unipersonal
      2011   Phase 2   EUCTR2010-022968-13-ES   Belgium;Spain